Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat bacterial infections including bacterial pneumonia, other respiratory tract infections, otitis media, strep throat, and cellulitis. It may also be used as an alternat. Cefdinir is an oral third generation cephalosporin that exerts bactericidal activity by binding to penicillin binding proteins and inhibiting bacterial cell wall synthesis, with useful activity against many common Gram positive and Gram negative respiratory pathogens. In clinical use it is formulated as the monohydrate and administered orally, typically once or twice daily depending on indication and patient renal function. Pharmacokinetic characteristics include moderate oral absorption, renal elimination of active drug and metabolites, and dose adjustments for reduced renal clearance. Analytical quality control relies on stability-indicating assays because the beta-lactam core is susceptible to hydrolysis and other degradation pathways.
Parent: Cefdinir
Parent: Cefdinir
Parent: Cefdinir
Parent: Cefdinir
Typical quality control specifications for cefdinir and its related substances follow pharmacopeial and ICH impurity guidelines; a representative specification used by manufacturers and testing labs sets total impurities not to exceed about 2.0 percent and any single unspecified impurity not to exceed about 0.5 percent, while specified known degradation or process-related impurities are often limited in the 0.1 to 0.5 percent range depending on identity and toxicity. Common related compounds and degradation products that are routinely monitored include beta-lactam hydrolysis products, deacetylated or decarboxylated derivatives, epimerization products at stereocenters, and minor process-related analogs; residual solvents and elemental impurity limits are controlled in accordance with ICH Q3C and Q3D guidance. Release testing typically comprises HPLC related-substance profiling, assay, water content, and microbiological and sterility attributes where applicable.
Cefdinir is used to treat bacterial infections such as community-acquired bacterial pneumonia, acute exacerbations of chronic bronchitis and other respiratory tract infections, acute otitis media, streptococcal pharyngitis, and uncomplicated skin and soft tissue infections caused by susceptible organisms; specific use should follow culture and susceptibility data and prescriber guidance.
Neither drug is categorically stronger; cefdinir and amoxicillin have different spectra of activity. Cefdinir, a third generation cephalosporin, generally offers broader Gram negative coverage while amoxicillin has reliable activity against many streptococci and Enterococcus species; choice depends on the pathogen, susceptibility results, infection site, and patient factors.
No, Cefdinir belongs to the cephalosporin class of beta-lactam antibiotics, which share the beta-lactam mechanism with penicillins but are a distinct chemical family. Cross-reactivity in patients with penicillin allergy is possible but less common than once assumed and should be evaluated on a case by case basis.
Yes, Cefdinir is classified as a third generation cephalosporin and displays the characteristic expanded Gram negative activity of this generation while retaining useful Gram positive coverage for many respiratory pathogens.
